雾化吸入药物疗法在COVI D-19治疗中的应用及药学监护  

Application and Pharmaceutical Care of Nebulized Inhaled Medication in the Treatment of COVID-19

作　　者：朱愿超[1] 吕俊玲[1] 李可欣[1] 齐文渊[1] 胡欣[1] Zhu Yuanchao;Lv Junling;Li Kexin;Qi Wenyuan;Hu Xin(Department of Pharmacy,Beijing Hospital,National Center of Gerontology,Institute of Geriatric Medicine,Chinese Academy of Medical Sciences,Beijing 100730,China)

机构地区：[1]北京医院药学部,国家老年医学中心,中国医学科学院老年医学研究院,北京100730

出　　处：《中国药事》2020年第5期520-529,共10页Chinese Pharmaceutical Affairs

基　　金：“国家重大新药创制”科技重大专项(编号2017zx09101001002002)。

摘　　要：新型冠状病毒肺炎(COVID-19)疫情在全世界蔓延,针对COVID-19的临床诊治与药物治疗研究成为热点。目前,尚没有针对COVID-19的特效药物或疫苗,而多项相关的药物临床试验迅速开展,也引起广泛的关注。截至2020年3月18日,共有8项雾化吸入疗法治疗COVID-19的临床试验在国家临床试验中心注册,涉及7种药物。本文介绍了这7种药物的应用研究进展和雾化吸入药学监护,以加强药品使用的风险管理,减少药品使用的不良事件。Corona virus disease 2019(COVID-19) outbreaks have been spreading around the world, and researches on COVID-19 have quickly become the hot topic. There is no specific drug or vaccine against COVID-19 so far. A number of related drug clinical trials have been carried out rapidly and have attracted much attention. Until Mar. 18 th, 2020, a total of 8 clinical trials of aerosol inhalation therapy for COVID-19 have been registered in National Clinical Trial Center, involving seven drugs. This article describes the application research of these drugs and pharmaceutical care of aerosol inhalation therapy, to strenghthen the risk management of drug use and reduce the adverse events of drug use.

关 键 词：雾化吸入 临床试验 新型冠状病毒肺炎 COVID-19 Α-干扰素 氯喹 药学监护 

分 类 号：R96[医药卫生—药理学]